News - Respiratory and Pulmonary

Filter

Current filters:

Respiratory and Pulmonary

Popular Filters

1 to 25 of 360 results

Strong first-half 2014 sales and earnings growth for Actelion

Strong first-half 2014 sales and earnings growth for Actelion

22-07-2014

Switzerland’s Actelion, Europe’s largest biotech company, this morning posted a strong set of financial…

ActelionBiotechnologyFinancialOrphan drugsRespiratory and Pulmonary

US breakthrough status for InterMune’s pirfenidone

US breakthrough status for InterMune’s pirfenidone

21-07-2014

US biotech firm InterMune’s Esbriet (pirfenidone) has been granted Breakthrough Therapy designation…

BiotechnologyEsbrietFood and Drug AdministrationInterMunepirfenidoneRare diseasesRegulationRespiratory and PulmonaryUSA

US breakthrough designation in IPF for Boehringer’s nintedanib

US breakthrough designation in IPF for Boehringer’s nintedanib

17-07-2014

The US Food and Drug Administration has granted Breakthrough Therapy designation for German family-owned…

Boehringer IngelheimnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

FDA accepts Teva’s NDA for albuterol MDPI

FDA accepts Teva’s NDA for albuterol MDPI

15-07-2014

Israel-based generic giant Teva Pharmaceuticals Industries says that the US Food and Drug Administration…

albuterolExercise-induced bronchospasmGenericsPulmonologyRegulationRespiratory and PulmonaryTeva Pharmaceutical IndustriesUSA

AstraZeneca licensing deal validates Synairgen’s approach, say analysts

AstraZeneca licensing deal validates Synairgen’s approach, say analysts

14-07-2014

Anglo-Swedish drug major AstraZeneca’s recent $230 million deal with British respiratory drug development…

AsthmaAstraZenecaBiotechnologyInterferonLicensingRespiratory and PulmonaryRespiratory therapySNG001SynairgenUK

GSK’s Anoro Ellipta approved in Japan for COPD

GSK’s Anoro Ellipta approved in Japan for COPD

04-07-2014

UK pharma giant GlaxoSmithKline and US partner Theravance said this morning that the Japanese Ministry…

Anoro ElliptaGlaxoSmithKlineJapanPharmaceuticalRespiratory and PulmonaryTheravance

FDA accepts Boehringer’s nintedanib NDA; granted priority review for IPF

FDA accepts Boehringer’s nintedanib NDA; granted priority review for IPF

02-07-2014

The US subsidiary of German family-owned drug major Boehringer Ingelheim says that the New Drug Application…

Boehringer IngelheimnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

Boehringer submits tiotropium + olodaterol Respimat for European approval in COPD

Boehringer submits tiotropium + olodaterol Respimat for European approval in COPD

02-07-2014

German family-owned pharma major Boehringer Ingelheim says it has submitted Marketing Authorization Applications…

Boehringer IngelheimEuropePharmaceuticalRegulationRespiratory and Pulmonarytiotropium + olodaterol Respimat

GSK and Theravance submit US sNDA for Breo Ellipta in asthma

GSK and Theravance submit US sNDA for Breo Ellipta in asthma

30-06-2014

US pharma giant GlaxoSmithKline and US partner Theravance have submitted a supplemental New Drug Application…

Breo ElliptaGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravanceUSA

EU5 payers looking to superior clinical efficacy for COPD

EU5 payers looking to superior clinical efficacy for COPD

30-06-2014

Surveyed pulmonologists in the European Union (EU5; France, Germany, Italy, Spain and the UK) estimate…

EuropeGlaxoSmithKlineMarkets & MarketingPharmaceuticalRelvarRespiratory and Pulmonary

Vectura signs additional deal with unnamed US pharma company

Vectura signs additional deal with unnamed US pharma company

30-06-2014

UK developer of inhaled therapies Vectura Group has signed a US collaboration, development and license…

LicensingPharmaceuticalRespiratory and PulmonaryUKUSAVecturaVR315

Vectura earns VR315 US development milestone

24-06-2014

UK developer of inhaled therapies Vectura Group says that it has triggered a milestone of $1.5 million…

FinancialPharmaceuticalResearchRespiratory and PulmonaryVecturaVR315

Stallergenes publishes review of grass pollen tablet confirming efficacy

Stallergenes publishes review of grass pollen tablet confirming efficacy

24-06-2014

French allergen specialist Stallergenes has released comprehensive new data on the 5-grass pollen immunotherapy…

FrancePharmaceuticalResearchRespiratory and PulmonaryStallergenes

Verona Pharma to drop VRP700 development after Phase IIa trial fails to meet endpoint

Verona Pharma to drop VRP700 development after Phase IIa trial fails to meet endpoint

23-06-2014

UK-based biotechnology company Verona Pharma says that the Phase IIa clinical trial to evaluate the efficacy…

PharmaceuticalResearchRespiratory and PulmonaryUKVerona Pharma

Teva reaches settlement with Perrigo in ProAir HFA patent case

Teva reaches settlement with Perrigo in ProAir HFA patent case

20-06-2014

Israeli generics giant Teva Pharmaceutical Industries has reached a settlement with Perrigo Pharmaceutical…

Catalent Pharma SolutionsGenericsLegalPatents & Trade marksPerrigoProair HFARespiratory and PulmonaryTeva Pharmaceutical IndustriesUSA

Actelion shares leap on positive Ph III data with selexipag

Actelion shares leap on positive Ph III data with selexipag

16-06-2014

Shares of Switzerland-based Actelion, Europe’s largest biotech firm, gained 15.1% to 104.70 Swiss francs…

ActelionBiotechnologyResearchRespiratory and Pulmonaryselexipag

ALK’s Japanese partner posts mixed results for house dust mite SLIT-tablet

ALK’s Japanese partner posts mixed results for house dust mite SLIT-tablet

16-06-2014

Denmark-based allergy specialist ALK Abello partner for Japan, Torii Pharmaceutical, has completed its…

ALK AbelloJapanPharmaceuticalRegulationResearchRespiratory and PulmonarySLIT-tabletTorii Pharma

AstraZeneca inks up to $232 million deal for Synairgen’s SNG001

AstraZeneca inks up to $232 million deal for Synairgen’s SNG001

12-06-2014

Anglo-Swedish pharma major AstraZeneca has signed a global licence accord with Synairgen, an AIM-listed…

AstraZenecaChronic lower respiratory diseasesHealth Medical PharmaLicensingMajorMedicinePharmaceuticalPulmonologyRespiratory and PulmonarySNG001Synairgen

Positive data on Incruse Ellipta added to Relvar/Breo Ellipta in COPD

Positive data on Incruse Ellipta added to Relvar/Breo Ellipta in COPD

11-06-2014

UK pharma giant GlaxoSmithKline and US partner Theravance have released positive results from two Phase…

Breo ElliptaGlaxoSmithKlineIncruse ElliptaPharmaceuticalRelvar ElliptaResearchRespiratory and PulmonaryTheravance

EAACI 2014: ALK presents positive Ph III data on house dust mite SLIT-tablet

EAACI 2014: ALK presents positive Ph III data on house dust mite SLIT-tablet

10-06-2014

Danish allergy specialist ALK-Abello has presented positive key trial results on its new sublingual allergy…

Alk-AbelloPharmaceuticalResearchRespiratory and PulmonarySLIT-tablet

EMA accepts Boehringer’s accelerated marketing application for nintedanib in IPF

EMA accepts Boehringer’s accelerated marketing application for nintedanib in IPF

05-06-2014

German family-owned pharma major Boehringer Ingelheim said this morning that the European Medicines Agency…

Boehringer IngelheimEuropenintedanibPharmaceuticalRegulationRespiratory and Pulmonary

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

05-06-2014

UK pharma giant GlaxoSmithKline has agreed to a $105 million settlement with 44 US states and the District…

AdvairFinancialGlaxoSmithKlineLegalMarkets & MarketingNeurologicalPaxilPharmaceuticalRespiratory and PulmonaryUSAWellbutrin

First Ph III data on Boehringer’s fixed-dose combo tiotropium plus olodaterol in COPD

22-05-2014

German family-owned drug major Boehringer Ingelheim has presented positive results of the VIVACITO (NCTO1559116)…

Boehringer IngelheimolodaterolPharmaceuticalResearchRespiratory and Pulmonarytiotropium

1 to 25 of 360 results

Back to top